Indegene Trades 61% Below Graham Number at 33x P/E
Indegene closed at ₹555.80 against a Graham Number of ₹1,278.09. The gap signals deep value but sits next to a 33.44x P/E.
company · 19 August 2026 · 4 min read
[Indegene](/stock/INDGN) (NSE: INDGN) closed at ₹555.80, a price that sits 61.2% below its Graham Number of ₹1,278.09, according to FairStock data. That gap is wide. The stock still carries a trailing P/E of 33.44 and a FairStock Score of 70. The discount and the multiple don't point in the same direction.
The Graham Number is a blunt tool. It multiplies earnings per share and book value per share, then takes the square root. For Indegene, the resulting floor of ₹1,278.09 assumes the market will pay for both asset value and normalized earnings. A 61% discount means the market is pricing in something outside that formula. Client concentration is one candidate. Contract renewal risk is another.
Indegene gets a large share of revenue from top-20 biopharma companies. That isn't unusual for the sector, but it does make quarterly results lumpy. One delayed clinical development program or a postponed regulatory submission can slow revenue. The 33.44x P/E leaves little room for that. If trailing earnings are close to peak, the Graham Number gap won't close by price rising. It will close by estimates falling.
Indegene's 61% Graham Discount vs Pharma IT Peers
The gap is not common among Indian pharma services names. [Syngene International](/stock/SYNGENE) (NSE: SYNGENE) trades at roughly 55x earnings and carries a valuation supported by manufacturing capacity, not just digital services. [L&T Technology Services](/stock/LTTS) (NSE: LTTS) trades near 34x earnings but has a broader engineering client base and different margin structure. Indegene's 33.44x P/E is lower than Syngene's but higher than the Nifty 50's trailing multiple of about 22x, NSE data show.
That matters. A stock can trade at a big Graham discount and still be expensive on forward earnings if growth decelerates. The 61.2% margin of safety is arithmetic. It's not a guarantee. The FairStock Score of 70 places INDGN in the upper band for mid-cap healthcare services, but the score alone doesn't settle the valua...
AI-generated market intelligence. Not investment advice.